Triazolam and zolpidem: A comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers

M. Z. Mintzer, J. M. Frey, J. E. Yingling, Roland R Griffiths

Research output: Contribution to journalArticle

Abstract

The psychomotor/cognitive performance, subject-rated, and observer-rated effects of single oral doses of the benzodiazepine hypnotic triazolam (0.125, 0.25, and 0.5 mg/70 kg) and the imidazopyridine hypnotic zolpidem (5, 10, and 20 mg/70 kg) were compared in 11 volunteers, in a double-blind, placebo-controlled, crossover design. Triazolam and zolpidem produced similar dose-related decrements on several performance measures, and similar dose-related increases on most observer-rated and several subject-rated measures. The drugs differed in the time course of their effects on these measures; the effects of zolpidem typically peaked 30 min earlier (1-1.5 h postdrug) than the effects of triazolam (1.5-2 h postdrug). Triazolam and zolpidem produced a different profile of effects on other performance measures which could not be attributed to time course differences. Triazolam produced significantly more impairment than zolpidem in time estimation. Triazolam, but not zolpidem, produced significant impairment on a short-term memory task. Zolpidem produced significantly more impairment than triazolam on several novel measures of performance on a computerized trail-making test. The observed differences between triazolam and zolpidem may be related to zolpidem's reported binding selectivity for the ω1 receptor subtype.

Original languageEnglish (US)
Pages (from-to)561-574
Number of pages14
JournalBehavioural Pharmacology
Volume8
Issue number6-7
StatePublished - 1997

Fingerprint

Triazolam
Healthy Volunteers
Hypnotics and Sedatives
Trail Making Test
Psychomotor Performance
zolpidem
Benzodiazepines
Short-Term Memory
Cross-Over Studies
Volunteers
Placebos

Keywords

  • Benzodiazepines
  • Cognitive
  • Human
  • Memory
  • Psychomotor
  • Subjective
  • Triazolam
  • Zolpidem

ASJC Scopus subject areas

  • Pharmacology
  • Neuroscience(all)

Cite this

Triazolam and zolpidem : A comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers. / Mintzer, M. Z.; Frey, J. M.; Yingling, J. E.; Griffiths, Roland R.

In: Behavioural Pharmacology, Vol. 8, No. 6-7, 1997, p. 561-574.

Research output: Contribution to journalArticle

@article{0619d40a03bf4866843d662b8edf7797,
title = "Triazolam and zolpidem: A comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers",
abstract = "The psychomotor/cognitive performance, subject-rated, and observer-rated effects of single oral doses of the benzodiazepine hypnotic triazolam (0.125, 0.25, and 0.5 mg/70 kg) and the imidazopyridine hypnotic zolpidem (5, 10, and 20 mg/70 kg) were compared in 11 volunteers, in a double-blind, placebo-controlled, crossover design. Triazolam and zolpidem produced similar dose-related decrements on several performance measures, and similar dose-related increases on most observer-rated and several subject-rated measures. The drugs differed in the time course of their effects on these measures; the effects of zolpidem typically peaked 30 min earlier (1-1.5 h postdrug) than the effects of triazolam (1.5-2 h postdrug). Triazolam and zolpidem produced a different profile of effects on other performance measures which could not be attributed to time course differences. Triazolam produced significantly more impairment than zolpidem in time estimation. Triazolam, but not zolpidem, produced significant impairment on a short-term memory task. Zolpidem produced significantly more impairment than triazolam on several novel measures of performance on a computerized trail-making test. The observed differences between triazolam and zolpidem may be related to zolpidem's reported binding selectivity for the ω1 receptor subtype.",
keywords = "Benzodiazepines, Cognitive, Human, Memory, Psychomotor, Subjective, Triazolam, Zolpidem",
author = "Mintzer, {M. Z.} and Frey, {J. M.} and Yingling, {J. E.} and Griffiths, {Roland R}",
year = "1997",
language = "English (US)",
volume = "8",
pages = "561--574",
journal = "Behavioural Pharmacology",
issn = "0955-8810",
publisher = "Lippincott Williams and Wilkins",
number = "6-7",

}

TY - JOUR

T1 - Triazolam and zolpidem

T2 - A comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers

AU - Mintzer, M. Z.

AU - Frey, J. M.

AU - Yingling, J. E.

AU - Griffiths, Roland R

PY - 1997

Y1 - 1997

N2 - The psychomotor/cognitive performance, subject-rated, and observer-rated effects of single oral doses of the benzodiazepine hypnotic triazolam (0.125, 0.25, and 0.5 mg/70 kg) and the imidazopyridine hypnotic zolpidem (5, 10, and 20 mg/70 kg) were compared in 11 volunteers, in a double-blind, placebo-controlled, crossover design. Triazolam and zolpidem produced similar dose-related decrements on several performance measures, and similar dose-related increases on most observer-rated and several subject-rated measures. The drugs differed in the time course of their effects on these measures; the effects of zolpidem typically peaked 30 min earlier (1-1.5 h postdrug) than the effects of triazolam (1.5-2 h postdrug). Triazolam and zolpidem produced a different profile of effects on other performance measures which could not be attributed to time course differences. Triazolam produced significantly more impairment than zolpidem in time estimation. Triazolam, but not zolpidem, produced significant impairment on a short-term memory task. Zolpidem produced significantly more impairment than triazolam on several novel measures of performance on a computerized trail-making test. The observed differences between triazolam and zolpidem may be related to zolpidem's reported binding selectivity for the ω1 receptor subtype.

AB - The psychomotor/cognitive performance, subject-rated, and observer-rated effects of single oral doses of the benzodiazepine hypnotic triazolam (0.125, 0.25, and 0.5 mg/70 kg) and the imidazopyridine hypnotic zolpidem (5, 10, and 20 mg/70 kg) were compared in 11 volunteers, in a double-blind, placebo-controlled, crossover design. Triazolam and zolpidem produced similar dose-related decrements on several performance measures, and similar dose-related increases on most observer-rated and several subject-rated measures. The drugs differed in the time course of their effects on these measures; the effects of zolpidem typically peaked 30 min earlier (1-1.5 h postdrug) than the effects of triazolam (1.5-2 h postdrug). Triazolam and zolpidem produced a different profile of effects on other performance measures which could not be attributed to time course differences. Triazolam produced significantly more impairment than zolpidem in time estimation. Triazolam, but not zolpidem, produced significant impairment on a short-term memory task. Zolpidem produced significantly more impairment than triazolam on several novel measures of performance on a computerized trail-making test. The observed differences between triazolam and zolpidem may be related to zolpidem's reported binding selectivity for the ω1 receptor subtype.

KW - Benzodiazepines

KW - Cognitive

KW - Human

KW - Memory

KW - Psychomotor

KW - Subjective

KW - Triazolam

KW - Zolpidem

UR - http://www.scopus.com/inward/record.url?scp=0030780231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030780231&partnerID=8YFLogxK

M3 - Article

C2 - 9832970

AN - SCOPUS:0030780231

VL - 8

SP - 561

EP - 574

JO - Behavioural Pharmacology

JF - Behavioural Pharmacology

SN - 0955-8810

IS - 6-7

ER -